Emily Xiao, MD
Cardiology · Bel Air, MDNPI 1629501242
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations.
Across 77 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$244
- Pfizer$212
- Kestra Medical Technology Services, Inc.$197
- Boehringer Ingelheim$145
- AstraZeneca$133
- Bayer$45
- plus $155 from 6 others
What the payments were for
- Food & beverage$1,130100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 30 | $244 |
| Pfizer | 22 | $212 |
| Kestra Medical Technology Services, Inc. | 3 | $197 |
| Boehringer Ingelheim | 5 | $145 |
| AstraZeneca | 7 | $133 |
| Bayer | 2 | $45 |
| Amgen | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Novo Nordisk | 1 | $17 |
How this compares
$1,130 in reported general payments places this provider in the 70th percentile of 44 cardiology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 49 | $961 |
| Atorvastatin Calcium | 61 | $712 |
| Metoprolol Succinate | 33 | $470 |
| Losartan Potassium | 18 | $286 |
| Amlodipine Besylate | 38 | $283 |
| Carvedilol | 28 | $221 |
| Spironolactone | 12 | $192 |
| Ezetimibe | 13 | $162 |
| ClopidogrelClopidogrel Bisulfate | 15 | $100 |
Paid to pharmacies, not to this prescriber.
Other cardiology in Bel Air
- Mohammadali HabibiBaltimore$15K
- Ayim Akyea DjamsonBeltsville$11K
- Michael WilberBaltimore$5K
- Eva HausnerovaChevy Chase$4K
- Hassanali KassamaliBaltimore$4K
- John ConditEaston$3K
- Pankaj LalRockville$3K
- Timothy ShanahanEaston$3K
- Anil SinghCumberland$2K
- Fayaz ShawlTakoma Park$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.